Grifols SA ADR
Grifols SA ADR (GRFS) Covered Calls
Grifols SA ADR trades in the Drug Manufacturers - General industry with an IV Rank of 54.37%, average versus the past year. GRFS's highest covered call setup is the $11.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 26.58% out of the money with 189 days to expiration, a 27.73% return until expiration, and a 53.56% theoretical annualized return. Across the setups shown, annualized returns run from 15.78% to 53.56% at strikes between $9.00 and $11.00, with 35 to 189 days to expiration, as of Nov 13, 2026.
Read more
Running GRFS covered calls helps you generate income from Grifols SA ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GRFS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If GRFS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GRFS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GRFS covered call is worth writing.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices.
| 2027-05-21 | 189 | 11.00 | 26.58 | 0.10 | 0.75 | 241.00 | 27.73 | 53.56 | -1.15 | +0.29 | 53 | 0.65 |
| 2026-12-18 | 35 | 9.00 | 3.57 | 0.10 | 0.30 | 41.00 | 4.72 | 49.20 | -1.15 | +0.38 | 445 | 0.20 |
| 2027-05-21 | 189 | 9.00 | 3.57 | 0.40 | 1.30 | 71.00 | 8.17 | 15.78 | -4.60 | +0.53 | 239 | 0.90 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank54.37% Moderate
- Market cap (M$)2,244
- 52 weeks high-11.05%
- 52 weeks low24.86%
- Analyst recommendationHold
2.60 - Target price$11.30
30.03% above the current stock price - Dividend—
- Payout ratio34.22%
- Earnings date2026-11-02
- P/E10.46
- Future P/E7.25
- EPS (ttm)0.83
- EPS growth next 5 years22.10%
As of Nov 13, 2026